

Pharmacy Formulary Updates for March 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status March 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO- MA
Mulpleta	\$3.65;PA;SP
Pifeltro	\$3.65
Lorbrena	\$3.65;PA;SP
Jivi	MB/RX;SP
Inveltys	\$3.65;PA
Xyosted	\$3.65;PA
Bryhali	\$3.65;PA
Benzoyl Peroxide 4% wash	\$3.65
Promacta powder	\$3.65;SP
Talzenna	\$3.65;PA;SP
Vizimpro	\$3.65;PA;SP
Aripiprazole Tabs	\$3.65;QL;PBHMI/Polypharmacy
Toremifene Citrate	\$3.65
Trelstar	MB/RX;SP

Key

MB: Medical Benefit

QL: Quantity Limitation

NC: Not covered

SP: Specialty Pharmacy - provided through CVS/specialty

NTM: New-to-market

ST: Step Therapy

PA: Prior Authorization

MB/RX: Drug can be dispensed through Medical Benefit or Prescription Benefit